RA Capital Management 13F holdings, Q1 2023
Holdings as of March 31, 2023 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 59 US equity positions worth $4.4bn in its Q1 2023 13F filing. The largest position was ASND at 16.9% of the reported book, followed by PCVX and DICE THERAPEUTICS INC. Against the Q4 2022 filing, it opened 4 new positions, added to 12 and reduced 2 among the top 50 holdings.
What did RA Capital Management own in Q1 2023? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2022 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 16.9% | $745.9m | 6,957,179 | 0% | held |
| 2 | PCVX VAXCYTE INC | Healthcare | 6.2% | $273.3m | 7,291,254 | 24% | added |
| 3 | DICE THERAPEUTICS INC | 5.1% | $225.1m | 7,856,612 | 15% | added | |
| 4 | 89BIO INC | 3.9% | $173.9m | 11,416,948 | 27% | added | |
| 5 | AEROVATE THERAPEUTICS INC | 3.8% | $166.7m | 8,263,982 | 0% | held | |
| 6 | BIIB BIOGEN INC | Healthcare | 3.4% | $148.2m | 532,892 | 0% | held |
| 7 | VRNA VERONA PHARMA PLC | 2.9% | $126.9m | 6,317,990 | 0% | held | |
| 8 | CTKB CYTEK BIOSCIENCES INC | Healthcare | 2.8% | $123.0m | 13,381,054 | 0% | held |
| 9 | VOR VOR BIOPHARMA INC | 2.8% | $122.4m | 22,748,880 | 0% | held | |
| 10 | LEGN LEGEND BIOTECH CORP | Healthcare | 2.7% | $117.5m | 2,436,223 | 0% | held |
| 11 | TYRA TYRA BIOSCIENCES INC | Healthcare | 2.6% | $116.3m | 7,236,454 | 0% | held |
| 12 | JANX JANUX THERAPEUTICS INC | Healthcare | 2.4% | $104.9m | 8,670,644 | 0% | held |
| 13 | PEPG PEPGEN INC | Healthcare | 2.3% | $99.5m | 8,131,952 | 0% | held |
| 14 | AVIDITY BIOSCIENCES INC | 2.2% | $98.5m | 6,416,998 | 18% | added | |
| 15 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.2% | $98.4m | 5,516,067 | 0% | held |
| 16 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 2.1% | $94.1m | 7,040,622 | 0% | held | |
| 17 | BELLUS HEALTH INC NEW | 2.1% | $91.0m | 12,643,574 | 2% | added | |
| 18 | CUREVAC N V | 1.9% | $85.4m | 12,245,955 | – | new | |
| 19 | IMMUNOGEN INC | 1.9% | $83.9m | 21,853,958 | 0% | held | |
| 20 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.7% | $74.5m | 17,202,009 | 0% | held |
| 21 | INHIBRX INC | 1.6% | $72.7m | 3,853,867 | 0% | held | |
| 22 | GERN GERON CORP | Healthcare | 1.5% | $68.5m | 31,544,806 | 144% | added |
| 23 | COGT COGENT COMMUNICATIONS HLDGS | Healthcare | 1.5% | $64.7m | 5,999,481 | 0% | held |
| 24 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.4% | $62.4m | 1,734,972 | -16% | reduced |
| 25 | ACRV ACRIVON THERAPEUTICS INC | 1.4% | $61.0m | 4,810,508 | 0% | held | |
| 26 | ITEOS THERAPEUTICS INC | 1.4% | $60.1m | 4,417,259 | 0% | held | |
| 27 | NEWAMSTERDAM PHARMA COMPANY | 1.2% | $53.0m | 4,000,000 | 0% | held | |
| 28 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.2% | $51.1m | 2,007,946 | 128% | added |
| 29 | RXST RXSIGHT INC | Healthcare | 1.2% | $50.9m | 3,052,796 | 0% | held |
| 30 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.1% | $49.8m | 3,178,476 | – | new |
| 31 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 1.1% | $46.9m | 1,762,000 | – | new |
| 32 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 1.1% | $46.5m | 2,122,465 | – | new |
| 33 | GHRS GH RESEARCH PLC | 1.0% | $44.6m | 5,581,161 | 14% | added | |
| 34 | ABOS ACUMEN PHARMACEUTICALS INC | 0.9% | $39.7m | 9,770,773 | 0% | held | |
| 35 | CLYM ELIEM THERAPEUTICS INC | 0.9% | $38.1m | 13,150,849 | 0% | held | |
| 36 | ANTX AN2 THERAPEUTICS INC | 0.8% | $37.2m | 3,773,517 | 0% | held | |
| 37 | ALPINE IMMUNE SCIENCES INC | 0.8% | $36.2m | 4,688,115 | 7% | added | |
| 38 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 0.8% | $35.6m | 4,398,453 | 0% | held |
| 39 | ICOSAVAX INC | 0.8% | $34.6m | 5,963,565 | 0% | held | |
| 40 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.7% | $33.1m | 11,609,704 | 22% | added |
| 41 | HILLEVAX INC | 0.7% | $29.1m | 1,760,019 | 0% | held | |
| 42 | NKTX NKARTA INC | Healthcare | 0.6% | $27.7m | 7,805,129 | 0% | held |
| 43 | KINNATE BIOPHARMA INC | 0.6% | $26.7m | 4,264,144 | 0% | held | |
| 44 | NANOSTRING TECHNOLOGIES | 0.6% | $24.3m | 2,457,273 | 1608% | added | |
| 45 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.4% | $19.6m | 3,009,678 | 0% | held |
| 46 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.4% | $19.4m | 1,131,775 | -53% | reduced |
| 47 | TNYA TENAYA THERAPEUTICS INC | 0.4% | $17.3m | 6,067,483 | 0% | held | |
| 48 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.4% | $17.1m | 2,971,231 | 0% | held |
| 49 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.4% | $16.2m | 3,426,286 | 0% | held |
| 50 | HOWL WEREWOLF THERAPEUTICS INC | 0.4% | $16.0m | 6,144,881 | 43% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.